Plain-English translation of NCT04156893 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether a more advanced way of matching donated blood — called RH genotype matching — can help patients with sickle cell disease who need regular transfusions. Instead of using the standard matching process, this study uses genetic information to find donor blood that is an even better match for each patient. The goal is to prevent the patient's immune system from developing a reaction against the transfused blood.
Patients with sickle cell disease often need regular blood transfusions to stay healthy, but their immune systems can develop reactions to foreign proteins in the donated blood over time. By matching blood more precisely using genetic information, researchers hope to prevent these harmful immune reactions and keep patients safer during their lifelong transfusion therapy.
You likely qualify if…
You likely don't qualify if…
You would continue receiving regular blood transfusions as you normally would, but the donated blood would be specially selected using genetic matching to provide a better match for your immune system. You would receive transfusions for the duration of your chronic transfusion therapy, or for up to three years in the study, whichever is shorter. The research team would monitor you to see whether this better matching reduces your risk of developing harmful immune reactions to the blood.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Phase
Safety & dosing / Early efficacy
Sponsor
Children's Hospital of Philadelphia
Collaborators
New York Blood Center, National Heart, Lung, and Blood Institute (NHLBI)
Enrollment target
~35 participants
Started
January 2020
Primary completion
April 2029
Age range
6 Months and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Stella Chou, MD
Children's Hospital of Philadelphia
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.